Nautilus Biotechnology (NAUT) Total Liabilities (2020 - 2026)

Nautilus Biotechnology has disclosed Total Liabilities across 7 years of filings, most recently posting $33.4 million for Q1 2026.

• Total Liabilities for Q1 2026 came in at $33.4 million, changed 0.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $33.4 million (changed 0.33% YoY), and the FY2025 annual result was $34.1 million, changed 0.37% from the prior year.
• Total Liabilities came in at $33.4 million for Q1 2026 at Nautilus Biotechnology, down from $34.1 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $42.2 million in Q1 2023 to a low of $31.8 million in Q3 2025.
• The 5-year median for Total Liabilities is $35.0 million (2022), against an average of $36.1 million.
• Across the five-year window, Total Liabilities jumped 956.92% in 2022 and declined 15.42% in 2024, its largest moves.
• Nautilus Biotechnology's Total Liabilities stood at $35.1 million in 2022, then advanced by 14.47% to $40.2 million in 2023, then slipped by 15.42% to $34.0 million in 2024, then advanced by 0.37% to $34.1 million in 2025, then decreased by 2.27% to $33.4 million in 2026.
• The last three Total Liabilities figures came in at $33.4 million (Q1 2026), $34.1 million (Q4 2025), and $31.8 million (Q3 2025), per Business Quant data.